Effectively Targeting Burkitt Lymphoma By Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer Cells Combined with a Histone Deacetylase Inhibitor, Romidepsin in Vitro and In Humanized NSG Mice  by Chu, Yaya et al.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170S152GRAFT PROCESSING
180
Correlation Between Pre-Collection CD34 Blood
Concentrations and CD34 Collection Yield in Difﬁcult-to-
Mobilize Patients Given Plerixafor: A Retrospective Single
Center Study
Odelia Amit, Ron Ram, Rinat Eshel, Esti Rom, Aviva Pinchasov,
Irit Avivi. Bone Marrow Transplant Unit, Tel Aviv Medical Center
and Sackler Faculty of Medicine, Tel Aviv, Israel
Background: Pre-collection CD34 blood concentrations have
been shown to predict collection yield in patients mobilized
with G-CSF +/- chemotherapy. We aimed to study this asso-
ciation in a cohort of difﬁcult to mobilize patients who were
given Plerixafor in addition to standard mobilization regimen.
Methods: We performed a retrospective cohort study of all
cases (n¼58) of patients (n¼31) who were difﬁcult to
mobilize and given Plerixafor prior to collection between the
years 2009 and 2014. Correlation between pre-collection
CD34 and collection yield was measured using the Pearson’s
chi squared test and goodness of ﬁt with a linear regression.
Two-sided p values are presented.
Results: Patients’ median age was 45 (range, 5e71) years,
54% were female. Baseline disease was lymphoma (74%),
Multiple Myeloma (10%) and solid malignancies (16%). Thirty
two percent of patients had >2 previous therapies, 36% prior
radiation therapy and 42% chemorefractory disease. Seventy
six percent of cases were collected at steady state (G-CSF +
Plerixafor) and 24% collected post chemotherapy and G-CSF.
There was a signiﬁcant correlation between pre-collec-
tion CD34 blood concentrations and CD34 collection yield
(r¼.93 (95% CI.88-.96, p<.001) with r2 in logistic regression of
.86, p<.001. Receiver operating curve to predict sufﬁcient
CD34 collection (Figure 1) showed at a pre-collection CD34
blood concentrations of >9.5 cells/ul sensitivity was 88%
(95% CI68.8-97.4) and speciﬁcity was 67.7% (95% CI48.6-
83.3). For CD34 blood concentrations >19 cells/ul sensitivity
was 84% (95% CI63.9-95.5) and speciﬁcity was 100% (95% CI
88.8-100.0). For CD34 blood concentrations of >9.5 cells/ul
and >19 cells/ul the negative predictive and positive pre-
dictive values were 69%, 92% and 100%, 88%, respectively.
Conclusion: Pre-collection CD34 blood concentration in
difﬁcult to mobilize patients given Plerixafor is a strong
predictor of successful collection with the value of >19 cells/
ul associated with 84% sensitivity and 100% speciﬁcity.Figure 1.181
Effectively Targeting Burkitt Lymphoma By Anti-CD20
Chimeric Antigen Receptor (CAR) Modiﬁed Expanded
Natural Killer Cells Combined with a Histone Deacetylase
Inhibitor, Romidepsin in Vitro and In Humanized
NSG Mice
YayaChu 1,AshlinYahr 1, JanetAyello 1,Mitchell S.Cairo 1,2,3,4,5.
1 Pediatrics, New York Medical College, Valhalla, NY;
2Microbiology and Immunology, New York Medical College,
Valhalla, NY; 3 Pathology, New York Medical College, Valhalla,
NY; 4 Cell Biology and Anatomy, New York Medical College,
Valhalla, NY; 5Medicine, New York Medical College, Valhalla, NYBackground: The outcome for patients with Burkitt lym-
phoma (BL) has improved signiﬁcantly but for patients who
relapse, the prognosis is dismal due to chemo-radiotherapy
resistance (Cairo et al, JCO, 2012). Our group has successfully
engineered expanded peripheral blood Natural Killer cells
(exPBNK) with an anti-CD20 chimeric antigen receptor (CAR
exPBNK) to target relapsed/resistant CD20+ BL cells in vitro
and in NSG mice (Chu & Cairo, ASH, 2013). Romidepsin, a
histone deacetylase inhibitor, enhances NKG2D ligands
expression (Satwani, Chu/Cairo, Cytotherapy 2014).
Objective:We investigated the combined effect of anti-CD20
CAR exPBNK cells with romidepsin against CD20+ BL in vitro
and in humanized NSG mice.
Methods: PBNK cells were expanded with inactivated K562-
mbIL15-41BBL cells and puriﬁed. Anti-CD20-4-1BB-CD3z
mRNA was nucleofected into exPBNK (Chu & Cairo, ASH,
2013). Raji, Raji-2R and Raji-4RH (provided by Matthew
Barth, MD) cells were treated with 10ng/ml romidepsin,
(Celgene Corp). MICA/B expression was analyzed by ﬂow
cytometry. NKG2D receptors were blocked using anti-NKG2D
antibodies (R & D systems). NK cytotoxicity was assessed by
europium release assays.
Romidepsin (2.2mg/kg) or PBS was i.p. injected into Raji-
Luc engrafted mice once a week for 3 weeks. 5x10*6 anti-
CD20 CAR exPBNK cells or mock exPBNK cells (without CAR
expression) were injected into each mouse 24hrs after each
romidepsin injection. Tumor regression and/or progression
was monitored by tumor volume measurements and by in
vivo bioluminescent imaging.
Results: MICA/B expression was signiﬁcantly increased in
rituximab sensitive Raji, resistant Raji-2R, and Raji-4RH cells
(P<0.001) after romidepsin treatment.
In vitro cytotoxicity of exPBNKwas signiﬁcantly enhanced
against romidepsin-treated tumor targets compared to the
untreated target cells at E:T¼3:1 (P<0.001).
Blocking NKG2D (99% to 18%) in exPBNK signiﬁcantly
reduced in vitro cytotoxicity against romidepsin treated tu-
mor targets compared to the unblocked exPBNK (P<0.001).
In vitro cytotoxicity of anti-CD20 CAR exPBNK cells was
signiﬁcantly enhanced against romidepsin-treated tumor
targets compared to the untreated at E:T¼3:1 (P<0.001), or
compared to the mock exPBNK (P<0.05) (Fig. 1A).
In humanized Raji xenograft NSG mice, the romidep-
sin+CAR exPBNK treated mice signiﬁcantly extended sur-
vival (surviving more than 100 days) compared to the
untreated (median 28 days, P<0.001), the mock exPBNK
treated mice (median 29 days, P<0.001), the CAR exPBNK
treated mice (median 42.5 days, P<0.05), the romidepsin
treated mice (median 30 days, P<0.001), and the romi-
depsin+mock exPBNK treated mice (median 34.5 days,
P<0.05) (Fig. 1B).
Conclusion: These results suggest the therapeutic potential
of the combination of anti-CD20 CAR exPBNK cells and
Figure 1.
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Successful Use of Cryopreservation and Shipping of CD34-
Selected Mismatched Related Donor Grafts for Treatment
of Children
Michael J. Eckrich 1, Carrie Barnhart 2, Ching-Ying Oon 3,
Stacy Epstein 4, Darci L. Grochowski 5, Javier Oesterheld 5,
Alexis Teplick 5, Sherman Bakabak 3, Morton J. Cowan 6,
Andrew Gilman 7. 1 Bone Marrow Transplant, Levine Children’s
Hospital at Carolinas Medical Center, Charlotte, NC; 2 Bone
Marrow Transplant, Carolinas Medical Center, Charlotte, NC;
3 University of California-UCSF, San Francisco, CA; 4 Pharmacy,
Carolinas Medical Center, Charlotte, NC; 5 Levine Children’s
Hospital-Carolinas Medical Center, Charlotte, NC; 6 Pediatric
Allergy Immunology and Blood and Marrow Transplant
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Background: T cell-depletion of haploidentical donor pe-
ripheral blood stem cell (PBSC) products is an important
modality that may expand the donor pool for trans-
plantation in pediatric patients. A survey of pediatric-center
directors shows that many pediatric centers do not have an
on-site stem cell processing laboratory (30%), and many
laboratories do not perform graft manipulation. The suc-
cessful use of cryopreserved grafts from centrally-processed
PBSC collections could expand the availability of this mo-
dality to pediatric centers without on-site stem cell pro-
cessing available.
Methods: Between 2009-2014, PBSCswere collected from 38
mismatched family member donors at Levine Children’sHospital, Charlotte, NC. Seventy PBSC apheresis procedures
were performed on-site for the 38 donor collections. PBSC
products were shipped on frozen gel packs to University of
California (UCSF) Stem Cell Processing Laboratory, per pro-
gram SOP and FACT guidelines. Validated thermal shipping
containers, with FACT compliant shipping labels, and door-
to-door delivery were used. Total costs included an average
$257 to ship each product. The product was inspected and
stored at 4C with next day processing. Processing with the
CD34+ selection by CliniMACS device took one day; prod-
ucts were immediately cryopreserved, then returned on the
day of transplant in a liquid nitrogen dry shipper.
Results: PBSC products were collected for 36 patients. Me-
dian donor age was 29 years (range 12-52). Median number
of apheresis collections was two (range 1-3). 34/36 patients
received a CD34+selected cryopreserved product for 21 ma-
lignant and 15 non-malignant diseases. One patient died
prior to transplant and one elected transplant elsewhere
with a different donor. Pre-processing viability was above
98% on all products. Median post-processing viability was
96% (range 84-99%). Median cell dose infused was
21x106CD34+/kg (range 8-24). There were no adverse events
with infusion. Engraftment (ANC>500) occurred in 33/34
patients, with median engraftment day of 14 days (range 9-
19). One primary graft failure occurred in a leaky-SCID pa-
tient, one secondary graft failure occurred, and both patients
engrafted after a second T cell-depleted mismatched donor
transplant. Shipping costs of PBSC in a dry shipper increased,
from a median $622 in 2009 to $922 in 2014.
Conclusions: An off-site stem cell processing laboratory was
used for CD34+ selection with the CliniMACS device. The
grafts were cryopreserved and shipped for transplant. The
manipulated PBSC grafts from mismatched related family
members were used for successful transplantation with
